Anabolic androgenic steroids accelerate brain aging

Philadelphia, March 25, 2021 –

Anabolic androgenic steroids (AAS), a synthetic version of the male sex hormone testosterone, are sometimes used as a medical treatment for hormone imbalance. But the vast majority of AAS is used to enhance athletic performance or build muscle because when paired with strength training. AAS use increases muscle mass and strength, and its use is known to have many side effects, ranging from acne to heart problems to increased aggression. A

new study

now suggests that AAS can also have deleterious effects on the brain, causing it to age prematurely.

The report appears in


Biological Psychiatry: Cognitive Neuroscience and Neuroimaging


, published by Elsevier.

“Anabolic steroid use has been associated with a range of medical and psychological side effects,” said lead author, Astrid Bjørnebekk, PhD, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. “However, since anabolic steroids have only been in the public domain for about 35 years, we are still in the early phase of appreciating the full scope of effects after prolonged use. The least studied effects are those that relate to the brain.”

Steroid hormones readily enter the brain, and receptors for sex hormones are found throughout the brain. Because AAS are administered at much higher doses than those naturally found in the body, they could have a harmful impact on the brain, particularly over a long period of use. Previous studies have shown that AAS users performed worse on cognitive tests than non-users.

Dr. Bjørnebekk and colleagues performed magnetic resonance imaging (MRI) of the brains of 130 male weightlifters with a history of prolonged AAS use and of 99 weightlifters who had never used AAS. Using a set of data compiled from nearly 2,000 healthy males from age 18 to 92 years of age. The researchers used machine learning to determine the predicted brain age of each of their participants and then determined the brain age gap: the difference between each participant’s chronological age and their predicted brain age. Advanced brain age is associated with impaired cognitive performance and increased risk for neurodegenerative diseases.

Not surprisingly, AAS users had a bigger brain age gap compared to non-users. Those with dependence on AAS, or with a longer history of use, showed accelerated brain aging. The researchers accounted for use of other substances and for depression in the men, which did not explain the difference between the groups.

“This important study shows in a large sample that use is associated with deviant brain aging, with a potential impact on quality of life in older age. The findings could be directly useful for health care professionals, and may potentially have preventive implications, where brain effects are also included into the risk assessment for young men wondering whether to use anabolic steroids,” added Dr. Bjørnebekk.

Cameron Carter, MD, editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, said of the study: “The results of this brain imaging study should be of concern for athletes using anabolic steroids for performance enhancement and suggest that the adverse effects on behavior and cognition previously shown to be associated with long-term use are the result of effects on the brain in the form of accelerated brain aging.”

###

Notes for editors

The article is “Long-term anabolic androgenic steroid use is associated with deviant brain aging,” by Astrid Bjørnebekk, Tobias Kaufmann, Lisa Hauger, Sandra Klonteig, Ingunn Hullstein, Lars Westlye (

https:/

/

doi.

org/

10.

1016/

j.

bpsc.

2021.

01.

001

). It appears as an Article in Press in

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

, published by

Elsevier

.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at

[email protected]

or +1 254 522 9700. Journalists wishing to interview the authors may contact Astrid Bjørnebekk at

[email protected]

or +47 9414 0625.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available

here

.

About

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging


is an official journal of the

Society of Biological Psychiatry

, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2019 Impact Factor score for

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

is 5.335.

http://www.

sobp.

org/

bpcnni

About Elsevier

As a global leader in information and analytics,

Elsevier

helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as

ScienceDirect

,

Scopus

,

SciVal

,

ClinicalKey

and

Sherpath

support strategic

research management

,

R&D performance

,

clinical decision support

, and

health education

. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including


The Lancet


and


Cell


, our 40,000 eBook titles; and our iconic reference works, such as

Gray’s Anatomy

. With the

Elsevier Foundation

and our external

Inclusion & Diversity Advisory Board

, we work in partnership with diverse stakeholders to advance

inclusion and diversity

in science, research and healthcare in developing countries and around the world.

Elsevier is part of

RELX

, a global provider of information-based analytics and decision tools for professional and business customers.

http://www.

elsevier.

com

Media contact


Rhiannon Bugno, Editorial Office


Biological Psychiatry: Cognitive Neuroscience and Neuroimaging


+1 254 522 9700


[email protected]